Taiwan Liposome Company EBIT

Taiwan Liposome Company (TLC) currently reports a EBIT of $-810M as of June 2021. That compares with $-920M in the prior-year period — up 11.5% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore Taiwan Liposome Company's EBIT history and peer comparisons.

Taiwan Liposome Company's EBIT increased from $-920M to $-810M — a 11.5% year-over-year increase (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taiwan Liposome Company's EBIT of $-810M is lower than the Healthcare sector average of $99B. That is roughly 100.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Taiwan Liposome Company reported $-810M in EBIT as of June 2021. That compares with $-920M in the prior-year period — up 11.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-810M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for Taiwan Liposome Company, and consider following TLC for alerts when major investors trade the stock.